{
    "clinical_study": {
        "@rank": "104137", 
        "arm_group": {
            "arm_group_label": "No Treatment"
        }, 
        "biospec_descr": {
            "textblock": "Whole Blood Venous Draw and Capillary Blood - IVD Study"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The Quo-Test A1C Analyzer and Reagent Test System (Quo-Test A1C System) are intended for the\n      in-vitro quantitative determination of glycated hemoglobin in whole blood samples obtained\n      from fingerstick or venous samples for point-of-care testing.  The Quo-Test A1C System is\n      indicated in the management and treatment of diabetes and for monitoring long term glycemic\n      control by diabetics.  It is for multiple patient use.  Only auto-disabling, single use\n      lancing devices should be used with this system."
        }, 
        "brief_title": "Reproducibility and Method Comparison Studies of the Quo-Test\u2122 A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test\u2122 A1C System", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 18 years or over\n\n          -  Able to read English\n\n          -  Read, understood and signed the Informed Consent Form\n\n          -  Agrees to participate and does not withdraw\\\n\n          -  Either healthy (without diabetes) or has Type 1 or Type 2 diabetes\n\n        Exlcusion Criteria:\n\n        \u2022 Declines participation or withdraws before study completion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "From site's patient database"
            }
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829061", 
            "org_study_id": "QDL Clinical Studies"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Type I Diabetes", 
            "Type II Diabetes", 
            "HbA1C"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Escondido", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92026"
                    }, 
                    "name": "AMCR Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chaska", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55318"
                    }, 
                    "name": "Ridgeview Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65212"
                    }, 
                    "name": "University of Missouri"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Reproducibility and Method Comparison of the Quo-Test\u2122 A1C System and the Quo-Lab A1C Test and CLIA Waiver of the Quo-Test\u2122 A1C System", 
        "overall_official": [
            {
                "affiliation": "AMCR Institute", 
                "last_name": "Tim Bailey, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ridgeview Research", 
                "last_name": "Stephanie Svoboda, PharmD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Missouri-Columbia", 
                "last_name": "Michael Gardner, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The objective is to conduct a method comparison between both the Quo-Test and Quo-Lab investigational devices and the reference method [Tosoh G8 (K071132)].  The reference method also serves as the predicate for the premarket notifications for both investigational devices.  Both capillary and venous samples will be tested on the Quo-Test A1C System and Quo-Lab A1C Test, while only venous samples will be tested on the reference method.", 
            "measure": "The objective is to conduct reproducibility testing using duplicates of each of 3 levels of HbA1C", 
            "safety_issue": "No", 
            "time_frame": "10 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Obtain CLIA Waiver Status for the Quo-Test", 
            "safety_issue": "No", 
            "time_frame": "10 Days"
        }, 
        "source": "Quotient Diagnostics Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Quotient Diagnostics Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}